RxDoctor Payments Data

Stephen Delcasino, PA

Physician Assistant · Las Vegas, NVNPI 1972944494

Payments from drug & device makers

$6,138in general payments, 2019–2025

Across 293 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$712
  • Dendreon Pharmaceuticals LLC$585
  • Boston Scientific$380
  • Antares Pharma, Inc.$305
  • Endo Pharmaceuticals Inc.$268
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$5,93097%
  • Education$2083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,138 in reported general payments places this provider in the 90th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$130,209
Medicare patients
471
Services billed
1,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$169,123
MyrbetriqMirabegron97$76,954
GemtesaVibegron78$60,862
XyostedTestosterone Enanthate25$15,240
Solifenacin Succinate85$6,285
Tamsulosin Hcl492$6,274
Testosterone Cypionate85$3,463
Alfuzosin Hcl ErAlfuzosin Hcl159$3,054
Finasteride212$2,775
Testosterone33$2,707
Methenamine Hippurate21$1,463
Estradiol23$1,422
Silodosin14$1,184
NitrofurantoinNitrofurantoin Macrocrystal29$797
Fesoterodine Fumarate ErFesoterodine Fumarate12$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,339$246,077109 claims
Sumitomo Pharma America, Inc.Gemtesa$712$60,86278 claims
Antares Pharma, Inc.Xyosted$305$15,24025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →